EMAIL DETAILS

Dear Friends of ACT *for* NIH:


*Today, we are announcing to the press and the research advocacy community
that Dr. Jim Allison is joining the ACT for NIH Advisory Committee. Dr.
Allison is the Chair of the Department of Immunology at the University of
Texas MD Anderson Cancer Center, and is Executive Director of the Center’s
Immunotherapy Platform. Work in his lab led to the development of
ipilumumab, an antibody which became the first new wave of cancer
immunotherapies and is prescribed to patients with metastatic melanoma,
cutaneous melanoma, renal cell carcinoma, and lung cancer. He is a member
of the National Academies of Science and Medicine, and he won the
Lasker-Debakey Clinical Medical Research Award in 2015. In the time I have
known Jim, he has been a persuasive advocate with Members of Congress who
want to know more about his work and NIH’s role in funding breakthrough
treatments.Attached is our press release, and we look forward to working
with such a prestigious advocate for the restoration of NIH funding. My
best,Pat WhitePresidentACT for NIH